Marlborough pharmaceutical manufacturer Sunovion is seeking federal approval for a drug to treat motor fluctuations in Parkinson’s disease patients.
The drug, apomorphine sublingual film, is being developed as a fast-acting treatment for motor fluctuations, or OFF episodes, in people living with the disease.
According to Sunovion, a study found the drug demonstrated superior efficacy versus placebo for the on-demand treatment of OFF episodes, with the drug’s effect persisting for at least 90 minutes.
The U.S. Food and Drug Administration has already granted fast-track designation for the treatment, but Sunovion said last week it has submitted a new drug application to the FDA.
Sunovion began working on the drug in October 2016 after the company acquired Canadian drugmaker Cynapsus Therapeutics for $624 million.
